APDN
Price
$0.85
Change
-$0.02 (-2.30%)
Updated
May 8 closing price
Capitalization
7.13M
RGEN
Price
$127.85
Change
+$0.97 (+0.76%)
Updated
May 8 closing price
Capitalization
10.26B
88 days until earnings call
Ad is loading...

APDN vs RGEN

Header iconAPDN vs RGEN Comparison
Open Charts APDN vs RGENBanner chart's image
Applied DNA Sciences
Price$0.85
Change-$0.02 (-2.30%)
Volume$744.93K
Capitalization7.13M
Repligen
Price$127.85
Change+$0.97 (+0.76%)
Volume$681.24K
Capitalization10.26B
APDN vs RGEN Comparison Chart
Loading...
APDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
APDN vs. RGEN commentary
May 09, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is APDN is a StrongBuy and RGEN is a Hold.

Ad is loading...
COMPARISON
Comparison
May 09, 2025
Stock price -- (APDN: $0.85 vs. RGEN: $127.85)
Brand notoriety: APDN and RGEN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: APDN: 45% vs. RGEN: 78%
Market capitalization -- APDN: $7.13M vs. RGEN: $10.26B
APDN [@Medical Specialties] is valued at $7.13M. RGEN’s [@Medical Specialties] market capitalization is $10.26B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

APDN’s FA Score shows that 1 FA rating(s) are green whileRGEN’s FA Score has 1 green FA rating(s).

  • APDN’s FA Score: 1 green, 4 red.
  • RGEN’s FA Score: 1 green, 4 red.
According to our system of comparison, RGEN is a better buy in the long-term than APDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

APDN’s TA Score shows that 2 TA indicator(s) are bullish while RGEN’s TA Score has 4 bullish TA indicator(s).

  • APDN’s TA Score: 2 bullish, 4 bearish.
  • RGEN’s TA Score: 4 bullish, 7 bearish.
According to our system of comparison, APDN is a better buy in the short-term than RGEN.

Price Growth

APDN (@Medical Specialties) experienced а -7.04% price change this week, while RGEN (@Medical Specialties) price change was -6.81% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.37%. For the same industry, the average monthly price growth was +9.27%, and the average quarterly price growth was -3.44%.

Reported Earning Dates

APDN is expected to report earnings on Aug 08, 2024.

RGEN is expected to report earnings on Aug 05, 2025.

Industries' Descriptions

@Medical Specialties (+0.37% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
RGEN($10.3B) has a higher market cap than APDN($7.13M). RGEN YTD gains are higher at: -11.178 vs. APDN (-91.707). RGEN has higher annual earnings (EBITDA): 134M vs. APDN (-12.2M). RGEN has more cash in the bank: 751M vs. APDN (3.36M). APDN has less debt than RGEN: APDN (1.12M) vs RGEN (712M). RGEN has higher revenues than APDN: RGEN (639M) vs APDN (9M).
APDNRGENAPDN / RGEN
Capitalization7.13M10.3B0%
EBITDA-12.2M134M-9%
Gain YTD-91.707-11.178820%
P/E RatioN/A247.52-
Revenue9M639M1%
Total Cash3.36M751M0%
Total Debt1.12M712M0%
FUNDAMENTALS RATINGS
APDN vs RGEN: Fundamental Ratings
APDN
RGEN
OUTLOOK RATING
1..100
156
VALUATION
overvalued / fair valued / undervalued
1..100
23
Undervalued
95
Overvalued
PROFIT vs RISK RATING
1..100
10086
SMR RATING
1..100
9890
PRICE GROWTH RATING
1..100
9860
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

APDN's Valuation (23) in the Information Technology Services industry is significantly better than the same rating for RGEN (95) in the Biotechnology industry. This means that APDN’s stock grew significantly faster than RGEN’s over the last 12 months.

RGEN's Profit vs Risk Rating (86) in the Biotechnology industry is in the same range as APDN (100) in the Information Technology Services industry. This means that RGEN’s stock grew similarly to APDN’s over the last 12 months.

RGEN's SMR Rating (90) in the Biotechnology industry is in the same range as APDN (98) in the Information Technology Services industry. This means that RGEN’s stock grew similarly to APDN’s over the last 12 months.

RGEN's Price Growth Rating (60) in the Biotechnology industry is somewhat better than the same rating for APDN (98) in the Information Technology Services industry. This means that RGEN’s stock grew somewhat faster than APDN’s over the last 12 months.

RGEN's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for APDN (100) in the Information Technology Services industry. This means that RGEN’s stock grew significantly faster than APDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
APDNRGEN
RSI
ODDS (%)
N/A
Bullish Trend 1 day ago
70%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
70%
MACD
ODDS (%)
N/A
Bearish Trend 1 day ago
65%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
77%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
74%
Advances
ODDS (%)
Bullish Trend 10 days ago
78%
Bullish Trend 15 days ago
75%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 2 days ago
80%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 2 days ago
70%
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
70%
View a ticker or compare two or three
Ad is loading...
APDN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
RGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
NPCT10.390.13
+1.27%
Nuveen Core Plus Impact Fund
WBIF27.270.30
+1.12%
WBI BullBear Value 3000 ETF
HTUS36.970.40
+1.09%
Hull Tactical US ETF
IUSV89.930.59
+0.66%
iShares Core S&P US Value ETF
IBDX24.70-0.09
-0.36%
iShares iBonds Dec 2032 Term Corp ETF

APDN and

Correlation & Price change

A.I.dvisor tells us that APDN and UFPT have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that APDN and UFPT's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To APDN
1D Price
Change %
APDN100%
-2.41%
UFPT - APDN
29%
Poorly correlated
+6.48%
POAI - APDN
28%
Poorly correlated
+5.94%
PRPO - APDN
27%
Poorly correlated
-0.73%
ATEC - APDN
24%
Poorly correlated
+2.33%
CODX - APDN
24%
Poorly correlated
+1.49%
More

RGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, RGEN has been loosely correlated with DHR. These tickers have moved in lockstep 65% of the time. This A.I.-generated data suggests there is some statistical probability that if RGEN jumps, then DHR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To RGEN
1D Price
Change %
RGEN100%
+0.76%
DHR - RGEN
65%
Loosely correlated
+0.90%
A - RGEN
60%
Loosely correlated
+1.10%
BIO - RGEN
57%
Loosely correlated
+3.64%
BLFS - RGEN
57%
Loosely correlated
N/A
TMO - RGEN
55%
Loosely correlated
+0.72%
More